Literature DB >> 19691928

Effects of inflammation on cholesterol metabolism: impact on systemic lupus erythematosus.

Allison B Reiss1.   

Abstract

Inflammation and dysregulated cholesterol metabolism are key components in the pathogenesis of atherosclerosis. Premature atherosclerosis is a characteristic feature of systemic lupus erythematosus. Although the cellular and molecular mechanisms underlying accelerated atherogenesis in lupus are not thoroughly understood, inflammation associated with the rheumatic disease state may promote atherosclerosis. Increasing evidence indicates that the systemic inflammatory load in lupus disrupts cholesterol homeostasis, increasing vulnerability to cholesterol accumulation in cells of the artery wall, including macrophages and endothelium. The relationship between the inflammatory state and dyslipidemia in lupus is complex, involving lipoproteins, cholesterol transporters, scavenger receptors, and oxysterols. The impact of lupus on each of these components of the cholesterol flux pathways is discussed. The formation of autoantibodies against epitopes within lipoprotein particles and their controversial role in atherogenesis is addressed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19691928     DOI: 10.1007/s11926-009-0036-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  49 in total

1.  Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies.

Authors:  E F Borba; E Bonfá
Journal:  Lupus       Date:  1997       Impact factor: 2.911

Review 2.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.

Authors:  D Steinberg; S Parthasarathy; T E Carew; J C Khoo; J L Witztum
Journal:  N Engl J Med       Date:  1989-04-06       Impact factor: 91.245

Review 3.  Atherosclerosis: immune and inflammatory aspects.

Authors:  Allison B Reiss; Amy D Glass
Journal:  J Investig Med       Date:  2006-04       Impact factor: 2.895

4.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

5.  Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women.

Authors:  M C Carr; A F Ayyobi; S J Murdoch; S S Deeb; J D Brunzell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-04-01       Impact factor: 8.311

6.  Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus.

Authors:  A Studnicka-Benke; G Steiner; P Petera; J S Smolen
Journal:  Br J Rheumatol       Date:  1996-11

7.  Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia.

Authors:  S L Nuttall; S Heaton; M K Piper; U Martin; C Gordon
Journal:  Rheumatology (Oxford)       Date:  2003-02-28       Impact factor: 7.580

8.  Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages.

Authors:  Allison B Reiss; Mohammad M Rahman; Edwin S L Chan; M Carmen Montesinos; Nahel W Awadallah; Bruce N Cronstein
Journal:  J Leukoc Biol       Date:  2004-06-14       Impact factor: 4.962

Review 9.  Atherosclerosis and systemic lupus erythematosus: the role of altered lipids and of autoantibodies.

Authors:  B H Hahn; M McMahon
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

10.  Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus.

Authors:  J R Batuca; P R J Ames; M Amaral; C Favas; D A Isenberg; J Delgado Alves
Journal:  Rheumatology (Oxford)       Date:  2008-11-10       Impact factor: 7.580

View more
  14 in total

1.  Semiquantified noncalcified coronary plaque in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Jens Vogel-Claussen; Armin Arbab-Zadeh; Laurence S Magder; Joao Lima; Michelle Petri
Journal:  J Rheumatol       Date:  2012-10-01       Impact factor: 4.666

Review 2.  Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches.

Authors:  Marianne Frieri
Journal:  Curr Allergy Asthma Rep       Date:  2012-02       Impact factor: 4.806

3.  Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis.

Authors:  Adnan N Kiani; Laurence S Magder; Wendy S Post; Moyses Szklo; Joan M Bathon; Pam J Schreiner; Daniel O'Leary; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2015-06-22       Impact factor: 7.580

4.  Association of a polymorphism of BTN2A1 with dyslipidemia in East Asian populations.

Authors:  Tetsuo Fujimaki; Kimihiko Kato; Mitsutoshi Oguri; Tetsuro Yohida; Hideki Horibe; Kiyoshi Yokoi; Sachiro Watanabe; Kei Satoh; Yukitoshi Aoyagi; Masashi Tanaka; Hiroto Yoshida; Shoji Shinkai; Yoshinori Nozawa; Dong-Jik Shin; Jong Ho Lee; Yangsoo Jang; Yoshiji Yamada
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

5.  Metabolic abnormalities and viral replication are associated with biomarkers of vascular dysfunction in HIV-infected children.

Authors:  T I Miller; W Borkowsky; L A DiMeglio; L Dooley; M E Geffner; R Hazra; E J McFarland; A J Mendez; K Patel; G K Siberry; R B Van Dyke; C J Worrell; D L Jacobson; William Shearer; Norma Cooper; Lynette Harris; Murli Purswani; Mahboobullah Baig; Anna Cintron; Ana Puga; Sandra Navarro; Doyle Patton; Sandra Burchett; Nancy Karthas; Betsy Kammerer; Ram Yogev; Kathleen Malee; Scott Hunter; Eric Cagwin; Andrew Wiznia; Marlene Burey; Molly Nozyce; Janet Chen; Elizabeth Gobs; Mitzie Grant; Katherine Knapp; Kim Allison; Patricia Garvie; Midnela Acevedo-Flores; Heida Rios; Vivian Olivera; Margarita Silio; Cheryl Borne; Patricia Sirois; Stephen Spector; Kim Norris; Sharon Nichols; Elizabeth McFarland; Emily Barr; Carrie Chambers; Douglas Watson; Nicole Messenger; Rose Belanger; Arry Dieudonne; Linda Bettica; Susan Adubato; Gwendolyn Scott; Lisa Himic; Elizabeth Willen
Journal:  HIV Med       Date:  2011-12-04       Impact factor: 3.180

Review 6.  Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.

Authors:  Allison B Reiss; Benna Jacob; Saba Ahmed; Steven E Carsons; Joshua DeLeon
Journal:  Inflammation       Date:  2021-04-05       Impact factor: 4.092

7.  Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment.

Authors:  Der-Yuan Chen; Hui-Min Chih; Joung-Liang Lan; Hsin-Yueh Chang; Wei-Wen Chen; En-Pei Isabel Chiang
Journal:  BMC Med       Date:  2011-01-13       Impact factor: 8.775

8.  Methotrexate in atherogenesis and cholesterol metabolism.

Authors:  Eric Coomes; Edwin S L Chan; Allison B Reiss
Journal:  Cholesterol       Date:  2011-02-22

9.  Association of genetic variants with dyslipidemia and chronic kidney disease in a longitudinal population-based genetic epidemiological study.

Authors:  Yoshiji Yamada; Kota Matsui; Ichiro Takeuchi; Tetsuo Fujimaki
Journal:  Int J Mol Med       Date:  2015-03-20       Impact factor: 4.101

10.  Altered expression of genes controlling metabolism characterizes the tissue response to immune injury in lupus.

Authors:  Amrie C Grammer; Peter E Lipsky; Kathryn M Kingsmore; Prathyusha Bachali; Michelle D Catalina; Andrea R Daamen; Sarah E Heuer; Robert D Robl
Journal:  Sci Rep       Date:  2021-07-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.